A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection

A Randomized, Parallel, Open-label Clinical Study on the Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects

This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.

Study Overview

• Status: Recruiting
• Conditions: Diabetes Mellitus
• Intervention / Treatment: Drug: SHR-3167 Injection

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Yanli Dong; Phone Number: +86-0518-82342973; Email: yanli.dong@hengrui.com
• Study Contact Backup: Name: Weijie Kong; Phone Number: +86-0518-82342973; Email: weijie.kong.wk1@hengrui.com

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410008
      • Recruiting
      • Xiangya Hospital, Central South University
      • Contact: Gan Zhou; Phone Number: +86-0731-89753401; Email: zhougan77@163.com
      • Principal Investigator: Gan Zhou

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male or female: 18 years old to 55 years old (on the day of signing the informed consent form).
2. For healthy subjects, the body mass index (BMI) should be between 19.0 kg/m² and 26.0 kg/m², and the weight of men should be ≥ 50 kg and that of women ≥ 45 kg.
3. Those who show no abnormalities through physical examination, vital signs, 12-lead electrocardiogram, frontal and lateral chest radiographs and laboratory tests, or have minor abnormalities but are judged by the researcher to have no clinical significance.
4. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must have no plans for conception or sperm/egg donation from the time of signing the informed consent form until 4 months after the last dose, and must voluntarily refrain from unprotected sexual activity within 14 days before the screening period and use effective contraceptive measures (including partners) during the study period; female subjects of childbearing potential must have no unprotected sexual activity in the past 14 days, have a negative pregnancy test during the screening period, and not be in the lactation period.
5. During the screening process, the fasting blood glucose should be between 3.9 mmol/L and 6.1 mmol/L, and the glycated hemoglobin (HbA1c) should be no more than 6.0%.
6. Understand the research procedures and methods, voluntarily participate and have the ability to comply with the requirements of the trial protocol to complete this trial, and sign the informed consent form in person.

Exclusion Criteria:

1. Those with a history of frequent allergies or allergic diseases, or those who, as judged by the researcher, may be allergic to the study drug or its components or foods, etc.
2. Those who have previously suffered from respiratory system, circulatory system, digestive system, urinary system, mental, nervous system, blood system, endocrine system, immune system or malignant tumor diseases, and who, based on the investigator's judgment, are not suitable to participate in this trial.
3. Exclude those who had severe infections, severe injuries or surgeries within the previous 12 weeks, or those who plan to undergo surgery during the trial.
4. Exclude those who have participated in any clinical trials of other drugs or medical devices within the previous 3 months prior to screening, or those who are still within 5 half-lives of the trial drug at the time of screening (whichever is longer).
5. Exclude those who have used any medication (including prescription drugs, over-the-counter drugs, herbal medicines, patent medicines, health supplements, etc.) within the previous 2 weeks up to the time of randomization.
6. Positive results were obtained for hepatitis B surface antigen (HBsAg), HIV antibody, Treponema pallidum specific antibody, or hepatitis C virus antibody tests; or the investigator judged that the subject was in the latent or active stage of the aforementioned infections.
7. Exclude those who have a history of blood donation within the past 12 weeks, or have suffered from severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within the past 12 weeks.
8. Those who received live (attenuated) vaccines within the previous 1 month or are scheduled to receive such vaccines during the trial process.
9. Those who have a history of drug use or substance abuse; or those who tested positive for drugs in the baseline visit.
10. Those who have difficulty in venous blood collection or whose physical condition does not allow for blood collection; or those who are expected not to comply well with the protocol or complete the entire trial follow-up.
11. Persons with incomplete civil capacity and without a valid guardian.
12. The researchers determined that any physical or psychological condition or illness that might increase the risk of the trial, affect the subjects' compliance with the protocol, or prevent the subjects from completing the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SHR-3167 Injection - Specification A Group	Drug: SHR-3167 Injection; SHR-3167 injection, different specifications.
Experimental: SHR-3167 Injection - Specification B Group	Drug: SHR-3167 Injection; SHR-3167 injection, different specifications.
Experimental: SHR-3167 Injection - Specification C Group	Drug: SHR-3167 Injection; SHR-3167 injection, different specifications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The maximum plasma concentration (Cmax)	Day 1 - Day 71.
The area under the blood drug concentration-time curve corresponding from time 0 to the last quantifiable concentration time (AUC0-t)	Day 1 - Day 71.
The area under the blood drug concentration-time curve from time 0 to infinity (AUC0-∞)	Day 1 - Day 71.

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to maximum plasma concentration (Tmax)	Day 1 - Day 71.
Terminal half-life (t1/2)	Day 1 - Day 71.
Apparent volume of distribution (Vz/F)	Day 1 - Day 71.
Safety: Incidence and severity of adverse events (AEs)	Day 1 - Day 71.
Anti-SHR-3167 antibody (ADA)	Day 1; Day 22; Day 71.
Apparent clearance (CL/F)	Day 1 - Day 71.

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 2, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: March 18, 2026
• First Submitted That Met QC Criteria: March 18, 2026
• First Posted (Actual): March 24, 2026

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Nutritional and Metabolic Diseases; Diabetes Mellitus
• Other Study ID Numbers: SHR-3167-106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No